Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Dexmedetomidine, Dexamethasone and Interscalene Block Duration After Arthroscopic Shoulder Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Elective ambulatory surgery patients undergoing arthroscopic shoulder surgery~* Including rotator cuff repair~* Stabilization procedures~* Acromioplasty~* Debridement and distal clavicle excision~Exclusion Criteria:~* Patient refusal~* Diabetes~* Pregnancy~* Coagulopathy significant enough to be a contraindication to regional anesthesia as determined by the attending anesthesiologist~* Sensitivity to local anesthetics, dexamethasone or dexmedetomidine~* Severe chronic obstructive pulmonary disease~* Contralateral vocal cord paralysis~* Contralateral diaphragmatic paralysis~* Surgical limb brachial plexus neuropathy~* Interscalene block site infection~* Systemic glucocorticoids in the last 2 weeks~* Epidural or intraarticular steroid injection in the past 3 months~* Chronic opioid use defined as daily use for the last two weeks~* Active peptic ulcer disease~* End-stage renal disease~* Cirrhotic liver disease~* Ventricular dysfunction~* Advanced heart block~* Previous participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): 4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): 50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
- Dexamethasone and Dexmedetomidine (Type: ACTIVE_COMPARATOR): 4 milligrams dexamethasone and 50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block

Based on this trial design, predict the completion outcome and termination type (if applicable).